Table 3.
Pharmacokinetics of the budesonide dosing cohorts.
| Budesonide dose (mg/kg) | ke | Half-life | Cmax | Cmax/Dose | AUC24 | AUC24/Dose |
|---|---|---|---|---|---|---|
| 1/h | h | ng/ml | (ng/ml)/(mg/kg) | (ng × h/m) | (ng × h/ml)/(mg/kg) | |
| 0.025 | 0.224 (40%) | 3.78 (57%) | 7.70 (57%) | 0.308 (57%) | 39.4 (39%) | 1.58 (39%) |
| 0.05 | 0.242 (26%) | 3.20 (37%) | 8.60 (71%) | 0.172 (71%) | 37.2 (57%) | 0.744 (57%) |
| 0.10 | 0.268 (43%) | 3.20 (56%) | 18.7 (35%) | 0.187 (35%) | 73.5 (44%) | 0.735 (44%) |
| ANOVA p value | 0.71 | 0.77 | 0.001 | 0.08 | 0.01 | 0.002 |
| Tukey p value | 0.025 vs. 0.05 | 0.95 | 0.11 | 0.99 | 0.007 | |
| 0.025 vs. 0.10 | 0.002 | 0.15 | 0.03 | 0.004 | ||
| 0.05 vs. 0.10 | 0.004 | 0.97 | 0.02 | 0.99 |
Data are calculated mean (%CV) pharmacokinetic parameter values for the three dose cohorts, as well as the p values from the ANOVA and Tukey post-hoc analyses.
ke elimination rate, Cmax maximum concentration, AUC24 area under the concentration 24-h time curve.